Compare BON & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BON | IMRN |
|---|---|---|
| Founded | 2006 | 1994 |
| Country | China | Australia |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.3M | 7.7M |
| IPO Year | 2020 | 2016 |
| Metric | BON | IMRN |
|---|---|---|
| Price | $1.14 | $0.92 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 10.1K | ★ 26.5K |
| Earning Date | 09-23-2026 | 08-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $385.87 | $16.39 |
| Revenue Next Year | $15.63 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.95 | $0.68 |
| 52 Week High | $2.06 | $1.99 |
| Indicator | BON | IMRN |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 38.44 |
| Support Level | $1.13 | $0.90 |
| Resistance Level | $1.22 | $1.00 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 57.79 | 19.96 |
Bon Natural Life Ltd focuses on the manufacturing of personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements by its customers. It has developed four technology platforms for large-scale separation, safety improvement, activity enhancement, and functional compounding of natural products. The company's offerings include Fragrance compounds, Health supplements, and Bioactive food ingredients. The company generates revenue from the sale of its products, the majority derived from the sale of Fragrance compounds, which include natural compounds extracted from plants for cosmetic applications.
Immuron Ltd is a commercial- and clinical-stage biopharmaceutical company focused on the development and commercialization of specifically targeted polyclonal antibodies. Its oral polyclonal antibodies offer delivery within the GI tract and can target viruses or bacteria and neutralize toxins at mucosal surfaces. The Company markets Travelan in Australia, an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of traveler's diarrhea and minor gastrointestinal disorders. Its products include Travelan, ProIBS and Protectyn. Its segments are Research and Development and Hyper-immune products, with Hyper-immune products generating maximum revenue. Australia generates maximum revenue.